Condition: Stage III Ovarian Cancer · Stage IV Ovarian Cancer · Stage III Primary Peritoneal Cancer · Sponsor: GOG Foundation
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC Arm will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (No HIPEC Arm) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per standard institutional guidelines +/- bevacizumab for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing +/- bevacizumab until progression or 36 months (if no evidence of disease).
This description comes directly from the study's public registry record.
Sarin Chhab · 215-854-0770 · schhab@gog.org
Shanon Matkin · 801-661-1584 · smatkin@gog.org
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of California San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Stanford Ambulatory Surgery Center Lane Operating Room | Palo Alto, California, United States | Recruiting |
| Stanford Women's Cancer Center | Palo Alto, California, United States | Recruiting |
| Stanford Hospital | Palo Alto, California, United States | Recruiting |
| University of Colorado Hospital - Anshutz Cancer Pavilion | Aurora, Colorado, United States | Recruiting |
| Hartford Hospital | Hartford, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital at Yale- New Haven | New Haven, Connecticut, United States | Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center | Coral Gables, Florida, United States | Recruiting |
| University of Miami Hospital and Clinics - Deerfield Beach | Deerfield Beach, Florida, United States | Recruiting |
+ 47 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05659381